Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes.

Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, Sahi J.

J Pharm Sci. 2012 Oct;101(10):3989-4002. doi: 10.1002/jps.23262. Epub 2012 Jul 17.

PMID:
22806329
2.

Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade.

Sudo M, Nishihara M, Takahashi J, Asahi S.

Drug Metab Dispos. 2017 Jul;45(7):734-736. doi: 10.1124/dmd.117.075234. Epub 2017 Apr 14.

PMID:
28411281
3.
4.

A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations.

Lahoz A, Donato MT, Montero S, Castell JV, Gómez-Lechón MJ.

Rapid Commun Mass Spectrom. 2008;22(2):240-4.

PMID:
18088071
5.

HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.

Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K.

J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):59-68. doi: 10.1016/j.vascn.2010.04.013. Epub 2010 May 9.

PMID:
20460162
6.

Metabolic activity of fresh and cryopreserved cynomolgus monkey (Macaca fascicularis) hepatocytes.

Hewitt NJ, Fischer T, Zuehlke U, Oesch F, Utesch D.

Xenobiotica. 2000 Jul;30(7):665-81.

PMID:
10963058
7.

Metabolic activity of cytochrome p450 isoforms in hepatocytes cryopreserved with wheat protein extract.

Grondin M, Hamel F, Sarhan F, Averill-Bates DA.

Drug Metab Dispos. 2008 Oct;36(10):2121-9. doi: 10.1124/dmd.108.021162. Epub 2008 Jul 10.

9.

The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.

Lundquist P, Lööf J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, Andersson TB.

Drug Metab Dispos. 2014 Mar;42(3):469-80. doi: 10.1124/dmd.113.054676. Epub 2014 Jan 6.

10.

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.

McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ.

Drug Metab Dispos. 2004 Nov;32(11):1247-53. Epub 2004 Jul 30.

11.

Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds.

Hultman Ia, Vedin C, Abrahamsson A, Winiwarter S, Darnell M.

Mol Pharm. 2016 Aug 1;13(8):2796-807. doi: 10.1021/acs.molpharmaceut.6b00396. Epub 2016 Jul 14.

PMID:
27377099
12.

Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer.

den Braver-Sewradj SP, den Braver MW, Vermeulen NP, Commandeur JN, Richert L, Vos JC.

Toxicol In Vitro. 2016 Jun;33:71-9. doi: 10.1016/j.tiv.2016.02.013. Epub 2016 Feb 26.

PMID:
26921663
13.

Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.

Donato MT, Lahoz A, Jiménez N, Pérez G, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ.

Drug Metab Dispos. 2006 Sep;34(9):1556-62. Epub 2006 Jun 8.

14.

Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance.

Jouin D, Blanchard N, Alexandre E, Delobel F, David-Pierson P, Lavé T, Jaeck D, Richert L, Coassolo P.

Eur J Pharm Biopharm. 2006 Jul;63(3):347-55. Epub 2006 Feb 23.

PMID:
16621491
15.

Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450.

Yajima K, Uno Y, Murayama N, Uehara S, Shimizu M, Nakamura C, Iwasaki K, Utoh M, Yamazaki H.

Drug Metab Dispos. 2014 May;42(5):867-71. doi: 10.1124/dmd.113.056804. Epub 2014 Feb 19.

16.

Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells.

Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolta JA, Willenbring H, Zern MA.

Stem Cells Transl Med. 2013 Jun;2(6):409-19. doi: 10.5966/sctm.2012-0160. Epub 2013 May 16.

17.

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.

Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM.

Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. Review.

PMID:
15364537
18.

Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes.

Lin C, Shi J, Moore A, Khetani SR.

Drug Metab Dispos. 2016 Jan;44(1):127-36. doi: 10.1124/dmd.115.066027. Epub 2015 Oct 9.

19.

Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device.

Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, Moliner P, Gallas JF, Fabre G, Klieber S.

Xenobiotica. 2015 Jan;45(1):29-44. doi: 10.3109/00498254.2014.944612. Epub 2014 Jul 28.

PMID:
25068923
20.

Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.

Zanelli U, Caradonna NP, Hallifax D, Turlizzi E, Houston JB.

Drug Metab Dispos. 2012 Jan;40(1):104-10. doi: 10.1124/dmd.111.042309. Epub 2011 Oct 13.

Supplemental Content

Support Center